Patent: 9,551,719

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 9,551,719

Title:	BCL-2-like protein 11 SRM/MRM assay
Abstract:	Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from the biological sample using the Liquid Tissue.TM. reagents and protocol, and the BIM protein is quantitated in the Liquid Tissue.TM. sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of a BIM peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
Inventor(s):	Krizman; David (Gaithersburg, MD), Hembrough; Todd (Gaithersburg, MD), Thyparambil; Sheeno (Frederick, MD), Liao; Wei-Li (Herndon, VA)
Assignee:	EXPRESSION PATHOLOGY, INC. (Rockville, MD)
Application Number:	13/942,574
Patent Claims:	see list of patent claims

Details for Patent 9,551,719

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	See Plans and Pricing	2031-01-13
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	See Plans and Pricing	2031-01-13
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	See Plans and Pricing	2031-01-13
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	See Plans and Pricing	2031-01-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.